Net net whichever way one does the comparison meirluc, it seems it would be very clear that DcVaxL works. This is what LL sensed way back in 2015 that made her to say 'Everyone is Living Longer'. I don't like the median way of assessing this immunotherapy trial but for the sake of simplicity we ended of abstracting this trial in terms of median survivals which is really not displaying the true efficacy of this drug. What I mean is there is no way of quantifying the k-m curve TAIL in these immunotherapy trials. Hopefully someone comes up with writing Abstracts in terms of quantifiable tails in immunotherapy trials. To date only there is narrative tails to write and charts to see but no quantifiable stick available, which is the limitation that we are living with now. And it throws like our mOS benefit is only a few months over the SOC but in reality we see the tail is really unbelievably huge, even years. And this becomes an easy spin or FUD target for Ex and AF et al short aides, thus DcVaxL becomes a victim of absence of quantifiable tail language, imo.
News 
Market Data 
Discover 
